The prognosis remains guarded in patients with HTC due to the lack of availability of a permanent cure. All the treatment options currently available focus on decreasing serum phosphate levels and symptomatic management. However, the presentation is quite variable in these patients, with some of them having very disabling symptoms while others not so symptomatic, though having a similar genetic and biochemical profile. Also, the growth of the tumoral calcinosis lesions is prolonged in mostÂ patients with significant remission of the symptoms with medical therapy.